-
CONTEXT-AWARE GENERATIVE AI FOR EVIDENCE GENERATION, ANALOG-DRIVEN ENROLLMENT FORECASTING, AND OPERATIONAL RISK MANAGEMENT IN ONCOLOGY TRIALS
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS AND POTENTIAL VALUE OF T-REGULATORY CELL THERAPY IN THE TREATMENT OF MODERATE-SEVERE CROHN’S DISEASE
Mar 18, 2026, 21:38 PM -
CLINICAL AND ECONOMIC BURDEN ASSOCIATED WITH PROLONGED AIR LEAKS AMONG PATIENTS UNDERGOING LOBECTOMY: A RETROSPECTIVE DATABASE ANALYSIS
Mar 18, 2026, 21:38 PM -
ECONOMIC EVALUATION AND BUDGET IMPACT ANALYSIS OF MICROWAVE ABLATION VS. RADIOFREQUENCY ABLATION AND SURGICAL RESECTION FOR EARLY-STAGE HEPATOCELLULAR CARCINOMA IN THE MEXICAN PUBLIC HEALTH SYSTEM
Mar 18, 2026, 21:38 PM -
STRATEGIC COMPARISON OF CENTER FOR PHARMACOECONOMICS AND INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW ECONOMIC EVALUATIONS
Mar 18, 2026, 21:38 PM -
MODELING APPROACHES FOR VACCINE INDIRECT EFFECTS IN ECONOMIC EVALUATIONS: A SCOPING REVIEW OF PUBLISHED REVIEWS AND METHODOLOGICAL GUIDANCE
Mar 18, 2026, 21:38 PM -
COST-UTILITY OF LIRAGLUTIDE VERSUS ORLISTAT FOR ADULT OBESITY MANAGEMENT IN SAUDI ARABIA A PAYER PERSPECTIVE ANALYSIS
Mar 18, 2026, 21:38 PM -
DECOMPOSITION OF GEOGRAPHIC VARIATION IN HEALTHCARE SPENDING
Mar 18, 2026, 21:38 PM -
FROM GPT-4 TO GPT-5.2: A COMPARATIVE EVALUATION OF LARGE LANGUAGE MODELS FOR EXTRACTING CLINICAL REAL-WORLD EVIDENCE DATA(RWE)
Mar 18, 2026, 21:38 PM -
IMPROVING AN ADHERENT PATIENT ANALYSIS OF THE DIABETES PREVENTION PROGRAM AND OUTCOMES STUDY
Mar 18, 2026, 21:38 PM -
COMPARING HTA DECISIONS, PRICING NEGOTIATIONS, AND REIMBURSEMENT OF INFLIXIMAB BIOLOGIC ORIGINATOR AND BIOSIMILARS IN CANADA
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF BIOLOGIC TREATMENTS IN ADULTS WITH SEVERE UNCONTROLLED EOSINOPHILIC ASTHMA: A U.S. PAYER PERSPECTIVE MARKOV MODEL
Mar 18, 2026, 21:38 PM -
THE FEASIBILITY OF MEASURING BTKI MEDICATION ADHERENCE IN THE TREATMENT OF CLL/SLL USING AN ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO) PLATFORM
Mar 18, 2026, 21:38 PM -
BUDGET IMPACT ANALYSIS OF DONISLECEL FOR ELIGIBLE ADULTS WITH TYPE I DIABETES IN THE UNITED STATES: AN ANALYSIS FROM A PAYER PERSPECTIVE
Mar 18, 2026, 21:38 PM -
ACCELERATING EVIDENCE GENERATION: LEVERAGING LLMS FOR FULL-TEXT STUDY SELECTION
Mar 18, 2026, 21:38 PM -
IMPACT OF COMORBID DEPRESSION ON INSULIN INITIATION AND CARDIOVASCULAR OUTCOMES AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS: A MULTINATIONAL OHDSI COHORT STUDY
Mar 18, 2026, 21:38 PM -
A MULTI-COUNTRY RETROSPECTIVE CHART REVIEW OF TREATMENT PATTERNS AND RESOURCE USE IN PATIENTS WITH NEWLY DIAGNOSED PH-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING FIRST-LINE CONSOLIDATION THERAPY
Mar 18, 2026, 21:38 PM -
IMPROVING REAL-WORLD ADOPTION OF HER2-LOW THERAPIES THROUGH TARGETED EDUCATIONAL INITIATIVES
Mar 18, 2026, 21:38 PM -
BEYOND SURVIVAL: HOW NON-HODGKIN LYMPHOMA IMPACTS WELL-BEING AND FINANCES COMPARED TO OTHER CANCERS
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS ANALYSIS OF RIBOCICLIB PLUS ENDOCRINE THERAPY (ET) VERSUS ABEMACICLIB PLUS ET IN THE ADJUVANT TREATMENT OF NODE POSITIVE PRE AND POSTMENOPAUSAL WOMEN WITH HR+/HER2- EARLY BREAST CANCER (EBC): A CANADIAN PAYER PERSPECTIVE
Mar 18, 2026, 21:38 PM
